Positive News SentimentPositive NewsNASDAQ:FATE Fate Therapeutics (FATE) Stock Price, News & Analysis $1.07 -0.03 (-2.73%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 08/1/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Fate Therapeutics Stock (NASDAQ:FATE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fate Therapeutics alerts:Sign Up Key Stats Today's Range$1.06▼$1.1150-Day Range$1.04▼$1.6752-Week Range$0.66▼$4.66Volume767,002 shsAverage Volume1.32 million shsMarket Capitalization$122.62 millionP/E RatioN/ADividend YieldN/APrice Target$3.83Consensus RatingHold Company Overview Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Read More Fate Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreFATE MarketRank™: Fate Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 189th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageFate Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Fate Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Fate Therapeutics are expected to decrease in the coming year, from ($1.63) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fate Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.25% of the outstanding shares of Fate Therapeutics have been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Fate Therapeutics has recently decreased by 0.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.70 Percentage of Shares Shorted8.25% of the outstanding shares of Fate Therapeutics have been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Fate Therapeutics has recently decreased by 0.84%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News SentimentN/A News SentimentFate Therapeutics has a news sentiment score of 1.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Fate Therapeutics this week, compared to 3 articles on an average week.Search Interest6 people have searched for FATE on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.51% of the stock of Fate Therapeutics is held by insiders.Percentage Held by Institutions97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fate Therapeutics' insider trading history. Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Stock News HeadlinesCould This Hawaii Community Be the Next Lahaina? Some Residents Fear a Similar Wildfire FateJuly 12, 2025 | msn.comSmall Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth (ADIA, FATE, MESO, CRSP)July 9, 2025 | theglobeandmail.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 2 at 2:00 AM | Brownstone Research (Ad)Rick Atkinson's 'The Fate of the Day' traces the middle years of the American RevolutionJuly 3, 2025 | yahoo.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comTMNT: Splintered Fate - Official Xbox Launch TrailerJune 26, 2025 | msn.comFate Therapeutics’ SWOT analysis: promising data boosts stock outlookJune 15, 2025 | investing.comFate Therapeutics, Inc.: Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission ...June 13, 2025 | finanznachrichten.deSee More Headlines FATE Stock Analysis - Frequently Asked Questions How have FATE shares performed this year? Fate Therapeutics' stock was trading at $1.65 at the beginning of the year. Since then, FATE shares have decreased by 35.2% and is now trading at $1.07. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) released its quarterly earnings data on Tuesday, May, 13th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.07. The biopharmaceutical company earned $1.63 million during the quarter, compared to analyst estimates of $1.18 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 47.17% and a negative net margin of 1,318.93%. Who are Fate Therapeutics' major shareholders? Fate Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.19%), Public Employees Retirement System of Ohio (0.10%) and Vanguard Personalized Indexing Management LLC (0.06%). Insiders that own company stock include Redmile Group, Llc, J Scott Wolchko, Bahram Valamehr, John Mendlein, Jerome Charles Bressi, Cindy Tahl, Yu-Waye Chu, Edward J Dulac III, Brian T Powl and Yuan Xu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fate Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Meta Platforms (META), Alibaba Group (BABA) and Netflix (NFLX). Company Calendar Last Earnings5/13/2025Today8/02/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FATE CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees550Year FoundedN/APrice Target and Rating Average Price Target for Fate Therapeutics$3.83 High Price Target$5.00 Low Price Target$2.00 Potential Upside/Downside+258.3%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$186.26 million Net Margins-1,318.93% Pretax Margin-1,318.93% Return on Equity-47.17% Return on Assets-34.60% Debt Debt-to-Equity RatioN/A Current Ratio8.81 Quick Ratio8.81 Sales & Book Value Annual Sales$13.63 million Price / Sales9.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.80 per share Price / Book0.38Miscellaneous Outstanding Shares114,600,000Free Float108,289,000Market Cap$122.62 million OptionableOptionable Beta2.24 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:FATE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.